Most evidence is preclinical. Human clinical data are limited; not an approved therapeutic.
TB-500 is a synthetic fragment related to Thymosin β4, a natural protein that helps organize the cell's internal scaffolding (the actin cytoskeleton).
Through its connection to actin regulation, the parent protein is involved in cell movement, blood-vessel formation, and dampening inflammation — and in animal models TB-500 has been linked to improved healing of muscle, tendon, and other tissue. Those are the mechanisms behind its use in recovery contexts.
As with BPC-157, the evidence base is largely preclinical. Some early human work exists on the parent protein, but TB-500 itself lacks adequate controlled human trials and is not an approved therapeutic.
Searching the published record…
Searching the published record…
Searching the published record…
Studies are surfaced live from the U.S. National Library of Medicine (PubMed). biohackr indexes and links the published record; it does not host or alter source articles.